Skip to main content

Somatrogon and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with somatrogon.

Major

Somatrogon Obesity

Major Potential Hazard, Moderate plausibility

human growth hormone - Prader-Willi Syndrome

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

References

  1. (2004) "Product Information. Serostim (somatropin)." Serono Laboratories Inc
  2. (2004) "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc
  3. (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
  4. (2023) "Product Information. Ngenla (somatrogon)." Pfizer U.S. Pharmaceuticals Group
View all 4 references
Moderate

Somatrogon Obesity

Moderate Potential Hazard, Moderate plausibility

somatrogon - diabetes mellitus

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.

References

  1. (2023) "Product Information. Ngenla (somatrogon)." Pfizer U.S. Pharmaceuticals Group

Somatrogon drug interactions

There are 430 drug interactions with somatrogon.

Somatrogon disease interactions

There are 8 disease interactions with somatrogon which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer